KAM
CTMX icon

Knightsbridge Asset Management’s CytomX Therapeutics CTMX Stock Holding History

Knightsbridge Asset Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-96,926
Closed -$177K – 124
2022
Q2 		$177K Buy
+96,926
New +$186K 0.04% 114

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Knightsbridge Asset Management's CTMX Position: Q3 2022 in Review

Knightsbridge Asset Management sold out of CytomX Therapeutics (CTMX) in Q3 2022, closing a stake of 96,926 shares — an estimated $177K sold.

Knightsbridge Asset Management first reported a position in CTMX in Q2 2022 and held it in 1 quarter. The position peaked at $177K in Q2 2022. 84 funds tracked by Wall St. Rank hold CTMX as of Q3 2022.

  • Knightsbridge Asset Management reported no remaining CytomX Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Knightsbridge Asset Management sold 96,926 CytomX Therapeutics shares in Q3 2022, an estimated $177K.
  • Knightsbridge Asset Management first reported a position in CytomX Therapeutics in Q2 2022 and held it in 1 quarter.
  • Knightsbridge Asset Management's CytomX Therapeutics position peaked at $177K in Q2 2022.
  • 84 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2022.

Based on Knightsbridge Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.